PapersPMID:20216298
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
What moved
1 findingHow to read these marks →- Increases HDL cholesterol
moderatereplicated ×2
“After 12 weeks, participants receiving ERN had a median HDL-c (interquartile range) increase of 3.0 mg/dl (0.75 to 5.0) compared with −1.0 mg/dl in controls (−6.0 to 2.5), P value is equal to 0.04.”
- Study
- RCT
- Duration
- 3 months
- Dose studied
- extended-release niacin (Niaspan) starting at 500 mg per night, titrated to a maximum tolerated dose not exceeding 1500 mg per night
- Population
- HIV-1-infected adults on stable antiretroviral therapy with low HDL-c (below 40 mg/dl) and LDL-c below 130 mg/dl, no statins or fibrates; randomised to extended-release niacin or an untreated control arm (no placebo)
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- HIV-infected adults on stable HAART with low HDL-c
- Participants
- 19
- Comparator
- no treatment
- Duration
- 84 days
- Endpoints measured
- 6